Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alere Inc (ALR) Surges on Amended Buyout News

Alere Inc (NYSE:ALR) has surged 16% in the pre-market after the Abbott Laboratories (NYSE:ABT) finally bit the bullet and agreed to an amended merger to buy Alere for $51 per share. Although $51 is lower than Abbott’s previous offer of $56 in cash per share, it is certainly good news for many Alere shareholders given the past circumstances. Abbott had previously wanted to back away from the deal altogether after the DOJ and other government agencies began probing Alere for various reasons. The two later went to court, with Abbott trying to terminate the merger and Alere trying to uphold the agreement. With today’s news, it seems that Alere was able to get the upper hand, albeit at a slightly lower price. The deal, which is worth around $5.3 billion, is expected to close by the end of Q3 2017. In addition, the two companies have agreed to dismiss their respective lawsuits against each other.

With the purchase, Abbott will gain more exposure to the fast growing point of care testing and medical device categories.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Our data shows that the smart money was pretty bullish on Alere in the fourth quarter. Of the 742 elite funds we track, 44 funds owned $997.26 million of Alere Inc (NYSE:ALR) and accounted for 29.40% of the float on December 31, versus 44 funds and $1.1 billion respectively on September 30. 2.6% of the float was short.

The Bottom Line

Alere Inc (NYSE:ALR) shares have soared on amended buyout news. Specifically, Abbott has agreed to buy Alere for $51 per share. For more reading, check out ‘7 Best Paying Healthcare Jobs That Allow You To Travel‘.

Follow Alere Inc. (NYSE:ALR)
Trade (NYSE:ALR) Now!


Wall Street Bull

Wall Street Bull

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.